Clinical Trial Update: Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated [Phase 4]

View source ↗

Summary

Phase 4 trial update examining the effects of losartan combined with an antiretroviral regimen containing raltegravir on fibrosis, inflammation mediators, cardi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Risk in HIV
• HIV Infection
• Hiv-associated Fibrosis

Drugs mentioned

• Losartan (losartan)
• raltegravir-containing antiretroviral regimen (raltegravir)

Snippet

Sponsor: Felipe Garcia | Conditions: HIV-1 Infection | Phase 4 | Status: COMPLETED | Results posted: 2019-08-02